Abstract: A method for manufacturing a honeycomb structure includes extrusion-molding honeycomb molded bodies. The honeycomb molded bodies are fired to form honeycomb fired bodies. A molding frame optionally having a vent portion with air permeability is provided. The honeycomb fired bodies are fixed in the molding frame. A member having an other vent portion with air permeability is optionally disposed on an inner face side of the molding frame. A gap between the honeycomb fired bodies and a gap between the molding frame and the honeycomb fired bodies are filled with a sealing material paste. The sealing material paste includes inorganic particles and/or inorganic fibers. The sealing material paste is dried to solidify the sealing material paste and to form an adhesive layer and a coat layer. The sealing material paste is in contact with at least a part of the vent portion during the drying.

Abstract: A method for manufacturing a honeycomb structure includes extrusion-molding honeycomb molded bodies. The honeycomb molded bodies are fired to form honeycomb fired bodies. A molding frame optionally having a vent portion with air permeability is provided. The honeycomb fired bodies are fixed in the molding frame. A member having an other vent portion with air permeability is optionally disposed on an inner face side of the molding frame. A gap between the honeycomb fired bodies and a gap between the molding frame and the honeycomb fired bodies are filled with a sealing material paste. The sealing material paste includes inorganic particles and/or inorganic fibers. The sealing material paste is dried to solidify the sealing material paste and to form an adhesive layer and a coat layer. The sealing material paste is in contact with at least a part of the vent portion during the drying.

Abstract: There is disclosed a diagnostic imaging agent which comprises a compound wherein at least one bifunctional ligand is chemically bonded to an amino group of amino oligosaccharide having the molecular weight of 500 to 2000 and having a reduction-treated reducing end of a sugar chain, or to an aldehyde group of a dialdehyde-oligosaccharide, at least one constituent monosaccharide of which is oxidation-cleaved, having the molecular weight of 500 to 2000 and having a reduction-treated reducing end of a sugar chain, and said ligand is coordinated with at least one metal ion selected from the group consisting of metal ions having the atomic number of 21-29, 31, 32, 37-39, 42-44, 49 and 56-83.